Active Pharmaceutical Ingredients CDMO Market: Industry Analysis and Forecast (2021-2027) by Drug, Product Type, Synthesis, Workflow, Drug, Application, and Region

Active Pharmaceutical Ingredients CDMO Market size was valued at US$ 86.6 Bn. in 2020 and expected to reach US$ 136.1 Bn. by 2027 at a CAGR of 6.7 % during the forecast period.

Active Pharmaceutical Ingredients CDMO Market Overview:

Active Pharmaceutical Ingredients CDMO is a company that deals with the manufacturing and development of active pharmaceutical ingredients and the outsourcing of services. This company is licensed and FDA approved to offer benefits to large organizations as well as growing pharmaceutical industries with fewer manufacturing facilities. Active Pharmaceutical Ingredients CDMO Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2026. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.

Active Pharmaceutical Ingredients CDMO Market Dynamics:

Rising research and development activities due to the high frequency of chronic diseases are likely to fuel the growth of innovative and generic drugs and their wide-ranging benefits. The biopharmaceutical sector has gained a lot of attention in the healthcare sector and is expected to eyewitness significant growth during the forecast period. A contract development and manufacturing company (CDMO) is responsible to offers drug development and manufacturing services. Pharmaceutical companies are collaborating with CDMO as a way to outsource drug development and drug manufacturing. Small biotechnology companies are hugely involved in contract manufacturing for manufacturing and outsourcing as CDMO being the convenient method for entering the market. In addition cost benefits of CDMO in manufacturing and promising benefits for budding industries is likely to fuel the growth of the market in the forecast period. As per Price water house Coopers highlight, the outsourcing sector and CDMO market is likely to grow with a CAGR of 6.9% and estimated to reach 160 billion by the end of 2027 and is likely to gain a strong presence in the market. The capability of large pharmaceutical industries to rely on sourced facilities and small pharmaceutical industries with a lack of in-house production facilities is offering wider opportunities for the CDMO market. Government authorization, issues related to quality, logistics, regulation, and intellectual property rights are making developing countries a less attractive option for pharmaceutical development outsourcing. This factor is likely to challenge the growth of the market. Active Pharmaceutical Ingredients CDMO Market Segment Analysis:

Traditional Active Pharmaceutical Ingredient Segment is dominating the Active Pharmaceutical Ingredients CDMO Market:

The traditional Active Pharmaceutical Ingredient segment is likely to gain more attraction in the product segment of the active pharmaceutical ingredient CDMO market. The growth of the market is attributed to the largest market share of around 40.5% in 2020. Moreover, the target drug delivery system in cancer and other treatments is likely to fuel the growth of the market. Further, technological development and innovations in APIs to offer better treatment and onset of drug action are likely to fuel the growth of the market. The antibody-drug conjugate is likely to gain a significant market share of 12.8% during the forecast period. Besides, the ADC biopharmaceutical sector is hitting the growth of the market due to increasing research and development activities in the application of ADC. This factor is likely to stimulate the growth of the market.

The synthetic segment is considered to supplement the growth of the Active Pharmaceutical Ingredients CDMO Market:

The synthetic segment is dominating the synthesis segment of the active pharmaceutical ingredient CDMO market with a market share of 74.5% in 2020. The growth of the segment is due to the abundant availability of raw materials and flexibility offered by the molecule in synthesis. Moreover, various synthetic ingredients are likely to go off patent and this factor is anticipated to create opportunities for the market players to invest in the market to generate more revenue during the forecast period. The biotech segment is growing at a high pace with a CAGR of 7.1% during the forecast period. The factors responsible for the growth of the market are amplified demand for higher molecular efficiency and the need for biopharmaceutical ingredients is likely to fuel the growth of the market in the coming future. Active Pharmaceutical Ingredients CDMO Market 1

The Innovative drug segment is gaining more attention in the Active Pharmaceutical Ingredient CDMO Market

The innovative drug segment is dominating the drug segment of the active pharmaceutical ingredient CDMO market with the largest market share of 72.9%. Owing to the growing rules and regulations imposed by the government authorizations and the approvals for the clinical trials together with the manufacturing of new molecules. Further, rising R & D activities are boosting the growth of new molecules approvals due to the innovation of unique molecules with better pharmacological actions. This is likely to prevail the growth of the market in the future. A generic drug is growing at a CAGR of 8.9% in the forecast period and the low cost of generic drugs and similar pharmacological action as compared to branded drugs are anticipated to shift the preference of consumers in the forecast period. And this factor is estimated to motivate the growth of the market. Oncology segment: New Trend of Application in the Active Pharmaceutical Ingredients CDMO Market: Oncology is leading in the application segment of the active pharmaceutical ingredient CDMO market and is estimated to account for the largest market share of 45.3% in 2020. The growth of the segment is attributed to innovative cancer therapies and the growing prevalence of cancer all over the globe. Besides oral chemotherapy is gaining more attention due to painful IV chemotherapies and adverse effects like vomiting, hair fall, low immune system, and dry throat, and various others. This factor is likely to boost the growth of the active pharmaceutical ingredient CDMO market in the forecast period.

Active Pharmaceutical Ingredients CDMO Market Regional Insights:

Asia Pacific dominates the Active Pharmaceutical Ingredients CDMO Market owing to increasing development strategies made by various industry verticals in the region and developing technologies that are boosting the regional market. The Asia Pacific region is anticipated to grow with a CAGR of 8.9% during the forecast period. Moreover, cost benefits in the Asia Pacific as compared to North America as the pharmaceutical ingredients in North America are expensive. Further, the growing countries of the Asia Pacific are China, India, and Japan. China is getting more attention in the market as the chemical market of China is growing at a high pace and is likely to dominate nationwide. China and India are some of the leading pharmaceutical ingredient providers globally. This factor is likely to boost the growth of the market. Increasing demand for medicines due to growing infectious diseases is likely to boost the growth of the market. Generic active pharmaceutical ingredient sales are exported to other countries from India and this sale has accounted for 40.65 of total sales in India and around 24.8% of sales in China. Moreover, China has around 30% of APIs vendors present in the market and India is among the second-largest providers of APIs and a major center for the outsourcing of APIs. This factor is likely to boost the growth of the market during the forecast period. North America is likely to grow with a significant market share. The US is a leading country in North America due to main pharmaceutical development outsourcing and the presence of research Organizations University Affiliated Pharmaceutical Research Cluster are likely to boost the growth of the market in the forecast period. Active Pharmaceutical Ingredients CDMO Market 2 The objective of the report is to present a comprehensive analysis of the Active Pharmaceutical Ingredients CDMO Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Active Pharmaceutical Ingredients CDMO Market dynamics, structure by analyzing the market segments and project the Active Pharmaceutical Ingredients CDMO Market size. Clear representation of competitive analysis of key players by Type, price, financial position, Type portfolio, growth strategies, and regional presence in the Active Pharmaceutical Ingredients CDMO Market make the report investor’s guide

Active Pharmaceutical Ingredients CDMO Market Scope: Inquire before buying

Active Pharmaceutical Ingredients CDMO Market 3

Active Pharmaceutical Ingredients CDMO Market, by Region

• North America • Asia Pacific • Europe • Latin America • Middle East & Africa

Active Pharmaceutical Ingredients CDMO Market Key Players

10x Genomics • Cambrex • Recipharm • Thermo Fisher Pantheon • Corden Pharma • Samsung Biologics • Lonza • Catalent • Siegfried • Piramal Pharma Solutions • Boehringer Ingelheim • catelent Inc. • Recipharm AB • Jubilant Life Science Ltd • Pathoeon Inc.

FAQs:

1. What is the Active Pharmaceutical Ingredients CDMO Market share in 2020? Ans: Approximately, 86.6 Million USD. 2. Which Drug segment is dominating the Active Pharmaceutical Ingredients CDMO Market? Ans: Innovative Drug segment is dominating the market for active pharmaceutical ingredients CDMO and accounted for 72.9% in 2020. The growth of the segment is attributed to growing FDA approvals. 3. Which workflow segment is expected to dominate the market during the forecast period? Ans: Commercial segment is considered to dominate the market and accounted for 88.2% in 2020. 4. Who are the key players in the active pharmaceutical ingredients CDMO market? Ans: Some key players operating in the API CDMO market include Cambrex, Recipharm, Thermo Fisher Pantheon, Corden Pharma, and Samsung Biologics. 5. What is the key driving factor for the growth of the Active Pharmaceutical Ingredients CDMO market? Ans: Key factors driving the API CDMO market growth include increased drug R&D, the rising incidence of chronic diseases, the expanding importance of generics, and the increasing consumption of biopharmaceuticals.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Active Pharmaceutical Ingredients CDMO Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Active Pharmaceutical Ingredients CDMO Market, By Size 3.4. Geographical Snapshot of the Active Pharmaceutical Ingredients CDMO Market, By Manufacturer share 4. Active Pharmaceutical Ingredients CDMO Market Overview, 2020-2027 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Technological Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Drug of Buyers/Consumers 4.1.6.3. Bargaining Drug of Suppliers 4.1.6.4. Threat of Substitute Technologies 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Active Pharmaceutical Ingredients CDMO Market 5. Supply Side and Demand Side Indicators 6. Active Pharmaceutical Ingredients CDMO Market Analysis and Forecast, 2020-2027 6.1. Active Pharmaceutical Ingredients CDMO Market Size & Y-o-Y Growth Analysis. 7. Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 7.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 7.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 7.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 7.1.3. Antibody-Drug Conjugate (ADC) 7.1.4. Other 7.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 7.2.1. Synthetic 7.2.2. Biotech 7.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 7.3.1. Innovative 7.3.2. Generic 7.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 7.4.1. Clinical 7.4.2. Commercial 7.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 7.5.1. Oncology 7.5.2. Hormonal 7.5.3. Glaucoma 7.5.4. Cardiovascular 7.5.5. Diabetes 7.5.6. Other 8. Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast by Region, 2020-2027 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 9.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 9.1.1. Traditional Active Pharmaceutical Ingredient (Traditional API) 9.1.2. Highly Potent Active Pharmaceutical Ingredient (HP-API) 9.1.3. Antibody-Drug Conjugate (ADC) 9.1.4. Other 9.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 9.2.1. Synthetic 9.2.2. Biotech 9.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 9.3.1. Innovative 9.3.2. Generic 9.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 9.4.1. Clinical 9.4.2. Commercial 9.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 9.5.1. Oncology 9.5.2. Hormonal 9.5.3. Glaucoma 9.5.4. Cardiovascular 9.5.5. Diabetes 10. North America Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 11.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 11.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 11.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 11.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 11.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 12. Canada Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 12.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 12.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 12.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 12.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 12.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 13. Mexico Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 13.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 13.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 13.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 13.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 13.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 14. Europe Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 14.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 14.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 14.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 14.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 14.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 15. Europe Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 16.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 16.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 16.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 16.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 16.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 17. France Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 17.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 17.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 17.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 17.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 17.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 18. Germany Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 18.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 18.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 18.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 18.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 18.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 19. Italy Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 19.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 19.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 19.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 19.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 19.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 20. Spain Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 20.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 20.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 20.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 20.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 20.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 21. Sweden Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 21.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 21.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 21.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 21.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 21.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 22. CIS Countries Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 22.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 22.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 22.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 22.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 22.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 23. Rest of Europe Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 23.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 23.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 23.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 23.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 23.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 24. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 24.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 24.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 24.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 24.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 24.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 25. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 26.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 26.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 26.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 26.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 26.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 27. India Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 27.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 27.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 27.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 27.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 27.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 28. Japan Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 28.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 28.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 28.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 28.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 28.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 29. South Korea Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 29.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 29.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 29.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 29.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 29.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 30. Australia Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 30.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 30.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 30.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 30.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 30.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 31. ASEAN Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 31.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 31.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 31.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 31.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 31.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 32. Rest of Asia Pacific Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 32.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 32.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 32.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 32.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 32.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 33. Middle East Africa Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 33.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 33.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 33.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 33.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 33.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 34. Middle East Africa Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 35.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 35.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 35.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 35.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 35.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 36. GCC Countries Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 36.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 36.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 36.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 36.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 36.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 37. Egypt Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 37.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 37.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 37.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 37.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 37.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 38. Nigeria Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 38.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 38.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 38.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 38.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 38.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 39. Rest of ME&A Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 39.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 39.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 39.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 39.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 39.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 40. South America Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 40.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 40.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 40.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 40.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 40.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 41. South America Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 42.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 42.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 42.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 42.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 42.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 43. Argentina Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 43.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 43.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 43.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 43.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 43.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 44. Rest of South America Active Pharmaceutical Ingredients CDMO Market Analysis and Forecasts, 2020-2027 44.1. Market Size (Value) Estimates & Forecast by Product Type, 2020-2027 44.2. Market Size (Value) Estimates & Forecast by Drug, 2020-2027 44.3. Market Size (Value) Estimates & Forecast by Synthesis, 2020-2027 44.4. Market Size (Value) Estimates & Forecast by Workflow, 2020-2027 44.5. Market Size (Value) Estimates & Forecast by Application, 2020-2027 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Active Pharmaceutical Ingredients CDMO Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players by Price, Presence, Market Share, and R&D Investment 45.2.2. New Synthesis Launches and Synthesis Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. 10x Genomics 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Synthesis Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Cambrex 45.3.3. Recipharm 45.3.4. Thermo Fisher Pantheon 45.3.5. Corden Pharma 45.3.6. Samsung Biologics 45.3.7. Lonza 45.3.8. Catalent 45.3.9. Siegfried 45.3.10. Piramal Pharma Solutions 45.3.11. Boehringer Ingelheim 45.3.12. catelent Inc. 45.3.13. Recipharm AB 45.3.14. Jubilant Life Science Ltd 45.3.15. Pathoeon Inc. 46. Primary Key Insights

About This Report

Report ID122726
Category Healthcare
Published DateOct 2021
Updated Date
Contact Us